Development of a Therapeutic Drug for Narcolepsy

Yoko Irukayama-Tomobe, Masashi Yanagisawa

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Narcolepsy-cataplexy is a debilitating disorder characterized by excessive daytime sleepiness and cataplexy, a bilateral loss of muscle tone triggered by positive emotions. The disease is caused by the loss of orexin-producing neurons in the hypothalamus. Currently, only symptom-oriented therapies are available for narcolepsy. We have recently discovered a potent, non-peptide orexin type-2 receptor (OX2R) agonist, YNT-185. We show that peripheral administration of YNT-185 significantly ameliorated the narcolepsy symptoms in a mouse model for narcolepsy. No desensitization was observed after repeated administration of YNT-185 with respect to the suppression of cataplexy-like episodes. These results provide a proof -of-concept for mechanistic therapy for narcolepsy-cataplexy using OX2R agonists. Additionally, YNT-185 promoted wakefulness in wild-type mice, suggesting that orexin receptor agonists may be useful for the treatment of excessive daytime sleepiness due to other conditions, such as sleepiness accompanying depression and sleepiness due to side effects of medicines or jet lag/shift work.

Original languageEnglish (US)
Pages (from-to)1255-1263
Number of pages9
JournalBrain and nerve = Shinkei kenkyu no shinpo
Volume70
Issue number11
DOIs
StatePublished - Nov 1 2018

Fingerprint

Narcolepsy
Cataplexy
Orexin Receptors
Pharmaceutical Preparations
Therapeutics
Wakefulness
Hypothalamus
Emotions
Depression
Neurons
Muscles

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Development of a Therapeutic Drug for Narcolepsy. / Irukayama-Tomobe, Yoko; Yanagisawa, Masashi.

In: Brain and nerve = Shinkei kenkyu no shinpo, Vol. 70, No. 11, 01.11.2018, p. 1255-1263.

Research output: Contribution to journalArticle

@article{e40626ef97834b0fb35c06695210dba5,
title = "Development of a Therapeutic Drug for Narcolepsy",
abstract = "Narcolepsy-cataplexy is a debilitating disorder characterized by excessive daytime sleepiness and cataplexy, a bilateral loss of muscle tone triggered by positive emotions. The disease is caused by the loss of orexin-producing neurons in the hypothalamus. Currently, only symptom-oriented therapies are available for narcolepsy. We have recently discovered a potent, non-peptide orexin type-2 receptor (OX2R) agonist, YNT-185. We show that peripheral administration of YNT-185 significantly ameliorated the narcolepsy symptoms in a mouse model for narcolepsy. No desensitization was observed after repeated administration of YNT-185 with respect to the suppression of cataplexy-like episodes. These results provide a proof -of-concept for mechanistic therapy for narcolepsy-cataplexy using OX2R agonists. Additionally, YNT-185 promoted wakefulness in wild-type mice, suggesting that orexin receptor agonists may be useful for the treatment of excessive daytime sleepiness due to other conditions, such as sleepiness accompanying depression and sleepiness due to side effects of medicines or jet lag/shift work.",
author = "Yoko Irukayama-Tomobe and Masashi Yanagisawa",
year = "2018",
month = "11",
day = "1",
doi = "10.11477/mf.1416201171",
language = "English (US)",
volume = "70",
pages = "1255--1263",
journal = "Brain and Nerve",
issn = "1881-6096",
publisher = "Igaku-Shoin Ltd",
number = "11",

}

TY - JOUR

T1 - Development of a Therapeutic Drug for Narcolepsy

AU - Irukayama-Tomobe, Yoko

AU - Yanagisawa, Masashi

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Narcolepsy-cataplexy is a debilitating disorder characterized by excessive daytime sleepiness and cataplexy, a bilateral loss of muscle tone triggered by positive emotions. The disease is caused by the loss of orexin-producing neurons in the hypothalamus. Currently, only symptom-oriented therapies are available for narcolepsy. We have recently discovered a potent, non-peptide orexin type-2 receptor (OX2R) agonist, YNT-185. We show that peripheral administration of YNT-185 significantly ameliorated the narcolepsy symptoms in a mouse model for narcolepsy. No desensitization was observed after repeated administration of YNT-185 with respect to the suppression of cataplexy-like episodes. These results provide a proof -of-concept for mechanistic therapy for narcolepsy-cataplexy using OX2R agonists. Additionally, YNT-185 promoted wakefulness in wild-type mice, suggesting that orexin receptor agonists may be useful for the treatment of excessive daytime sleepiness due to other conditions, such as sleepiness accompanying depression and sleepiness due to side effects of medicines or jet lag/shift work.

AB - Narcolepsy-cataplexy is a debilitating disorder characterized by excessive daytime sleepiness and cataplexy, a bilateral loss of muscle tone triggered by positive emotions. The disease is caused by the loss of orexin-producing neurons in the hypothalamus. Currently, only symptom-oriented therapies are available for narcolepsy. We have recently discovered a potent, non-peptide orexin type-2 receptor (OX2R) agonist, YNT-185. We show that peripheral administration of YNT-185 significantly ameliorated the narcolepsy symptoms in a mouse model for narcolepsy. No desensitization was observed after repeated administration of YNT-185 with respect to the suppression of cataplexy-like episodes. These results provide a proof -of-concept for mechanistic therapy for narcolepsy-cataplexy using OX2R agonists. Additionally, YNT-185 promoted wakefulness in wild-type mice, suggesting that orexin receptor agonists may be useful for the treatment of excessive daytime sleepiness due to other conditions, such as sleepiness accompanying depression and sleepiness due to side effects of medicines or jet lag/shift work.

UR - http://www.scopus.com/inward/record.url?scp=85056314665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056314665&partnerID=8YFLogxK

U2 - 10.11477/mf.1416201171

DO - 10.11477/mf.1416201171

M3 - Article

C2 - 30416119

AN - SCOPUS:85056314665

VL - 70

SP - 1255

EP - 1263

JO - Brain and Nerve

JF - Brain and Nerve

SN - 1881-6096

IS - 11

ER -